Illumina, Inc. (ILMN) recently entered into an agreement with Janssen Research & Development, LLC (Janssen) to develop its novel molecular residual disease (MRD) assay. The assay is a multi-cancer whole- genome sequencing (WGS) research solution that detects circulating tumor DNA (ctDNA) to better understand disease persistence or recurrence following treatment intervention. It is worth mentioning that MRD testing is increasingly being used in cancer as a predictive indication of disease recurrence followin ...